{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:38:37Z","timestamp":1793763517295,"version":"4.6.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["programme grant"],"award-info":[{"award-number":["programme grant"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["Programmatic funding"],"award-info":[{"award-number":["Programmatic funding"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_16047"],"award-info":[{"award-number":["MC_PC_16047"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C20807\/A28640"],"award-info":[{"award-number":["C20807\/A28640"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C20807\/A28640"],"award-info":[{"award-number":["C20807\/A28640"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A24881"],"award-info":[{"award-number":["A24881"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["Programmatic funding"],"award-info":[{"award-number":["Programmatic funding"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Site de Recherche Integree sur le Cancer (SiRIC2) Institute Curie"},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["20839"],"award-info":[{"award-number":["20839"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>SF3B1<\/jats:italic> hotspot mutations are associated with a poor prognosis in several tumor types and lead to global disruption of canonical splicing. Through synthetic lethal drug screens, we identify that <jats:italic>SF3B1<\/jats:italic> mutant (<jats:italic>SF3B1<\/jats:italic><jats:sup>MUT<\/jats:sup>) cells are selectively sensitive to poly (ADP-ribose) polymerase inhibitors (PARPi), independent of hotspot mutation and tumor site. <jats:italic>SF3B1<\/jats:italic><jats:sup>MUT<\/jats:sup> cells display a defective response to PARPi-induced replication stress that occurs via downregulation of the cyclin-dependent kinase 2 interacting protein (CINP), leading to increased replication fork origin firing and loss of phosphorylated CHK1 (pCHK1; S317) induction. This results in subsequent failure to resolve DNA replication intermediates and G<jats:sub>2<\/jats:sub>\/M cell cycle arrest. These defects are rescued through CINP overexpression, or further targeted by a combination of ataxia-telangiectasia mutated and PARP inhibition. In vivo, PARPi produce profound antitumor effects in multiple <jats:italic>SF3B1<\/jats:italic><jats:sup>MUT<\/jats:sup> cancer models and eliminate distant metastases. These data provide the rationale for testing the clinical efficacy of PARPi in a biomarker-driven, homologous recombination proficient, patient population.<\/jats:p>","DOI":"10.1038\/s41588-023-01460-5","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T16:02:56Z","timestamp":1690819376000},"page":"1311-1323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response"],"prefix":"10.1038","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1370-0359","authenticated-orcid":false,"given":"Philip","family":"Bland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty T.","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Curnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Muirhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4672-9684","authenticated-orcid":false,"given":"Jadwiga","family":"Nieminuszczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Beatrix","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaieh","family":"Hedayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9350-5520","authenticated-orcid":false,"given":"Holly E.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8378-9112","authenticated-orcid":false,"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-2619","authenticated-orcid":false,"given":"Ioanna","family":"Mavrommati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-8495","authenticated-orcid":false,"given":"Barrie","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Gazinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen N.","family":"Pemberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Guppy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Roxanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-8970","authenticated-orcid":false,"given":"Ceri","family":"Oldreive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-274X","authenticated-orcid":false,"given":"Tatjana","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kalirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Coupland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-1346","authenticated-orcid":false,"given":"Samar","family":"Alsafadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6267-2353","authenticated-orcid":false,"given":"Alexandre","family":"Houy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-2272","authenticated-orcid":false,"given":"Marc-Henri","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-3857","authenticated-orcid":false,"given":"Stephen","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-5477","authenticated-orcid":false,"given":"Jyoti S.","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-5480","authenticated-orcid":false,"given":"Syed","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8518-6304","authenticated-orcid":false,"given":"Wojciech","family":"Niedzwiedz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-0515","authenticated-orcid":false,"given":"Christopher J.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-2946","authenticated-orcid":false,"given":"Rachael","family":"Natrajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"1460_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","volume":"13","author":"RB Darman","year":"2015","unstructured":"Darman, R. B. et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3\u2032 splice site selection through use of a different branch point. Cell Rep. 13, 1033\u20131045 (2015).","journal-title":"Cell Rep."},{"key":"1460_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","volume":"23","author":"M Seiler","year":"2018","unstructured":"Seiler, M. et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 23, 282\u2013296 (2018).","journal-title":"Cell Rep."},{"key":"1460_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia, J. et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645\u2013651 (2018).","journal-title":"Nat. Genet."},{"key":"1460_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399\u2013405 (2012).","journal-title":"Nature"},{"key":"1460_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.2523","volume":"45","author":"JW Harbour","year":"2013","unstructured":"Harbour, J. W. et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45, 133\u2013135 (2013).","journal-title":"Nat. Genet."},{"key":"1460_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","volume":"150","author":"M Imielinski","year":"2012","unstructured":"Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107\u20131120 (2012).","journal-title":"Cell"},{"key":"1460_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714\u2013726 (2013).","journal-title":"Cell"},{"key":"1460_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/path.4483","volume":"235","author":"SL Maguire","year":"2015","unstructured":"Maguire, S. L. et al. SF3B1 mutations constitute a novel therapeutic target in breast cancer. J. Pathol. 235, 571\u2013580 (2015).","journal-title":"J. Pathol."},{"key":"1460_CR9","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384\u20131395 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1460_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64\u201369 (2011).","journal-title":"Nature"},{"key":"1460_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"1460_CR12","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"1460_CR13","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/s41375-020-0839-4","volume":"34","author":"SA Bamopoulos","year":"2020","unstructured":"Bamopoulos, S. A. et al. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia 34, 2621\u20132634 (2020).","journal-title":"Leukemia"},{"key":"1460_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/leu.2014.196","volume":"29","author":"P Baliakas","year":"2015","unstructured":"Baliakas, P. et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 29, 329\u2013336 (2015).","journal-title":"Leukemia"},{"key":"1460_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00862-6","volume":"13","author":"C Callens","year":"2021","unstructured":"Callens, C. et al. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. Genome Med. 13, 44 (2021).","journal-title":"Genome Med."},{"key":"1460_CR16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-18-4044","volume":"26","author":"A Pearson","year":"2020","unstructured":"Pearson, A. et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. Clin. Cancer Res. 26, 608\u2013622 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1460_CR17","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1182\/bloodadvances.2021004556","volume":"5","author":"I van der Werf","year":"2021","unstructured":"van der Werf, I. et al. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. Blood Adv. 5, 3254\u20133265 (2021).","journal-title":"Blood Adv."},{"key":"1460_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","volume":"123","author":"S Yavuzyigitoglu","year":"2016","unstructured":"Yavuzyigitoglu, S. et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology 123, 1118\u20131128 (2016).","journal-title":"Ophthalmology"},{"key":"1460_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10615","volume":"7","author":"S Alsafadi","year":"2016","unstructured":"Alsafadi, S. et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun. 7, 10615 (2016).","journal-title":"Nat. Commun."},{"key":"1460_CR20","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","volume":"3","author":"SJ Furney","year":"2013","unstructured":"Furney, S. J. et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 3, 1122\u20131129 (2013).","journal-title":"Cancer Discov."},{"key":"1460_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","volume":"34","author":"A Kahles","year":"2018","unstructured":"Kahles, A. et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell 34, 211\u2013224 (2018).","journal-title":"Cancer Cell"},{"key":"1460_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/onc.2016.279","volume":"36","author":"AK Kesarwani","year":"2017","unstructured":"Kesarwani, A. K. et al. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3\u2032 splice sites within RNA secondary structures. Oncogene 36, 1123\u20131133 (2017).","journal-title":"Oncogene"},{"key":"1460_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2016.08.036","volume":"64","author":"C Cretu","year":"2016","unstructured":"Cretu, C. et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol. Cell 64, 307\u2013319 (2016).","journal-title":"Mol. Cell"},{"key":"1460_CR24","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/leu.2014.28","volume":"28","author":"D Gentien","year":"2014","unstructured":"Gentien, D. et al. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages. Leukemia 28, 1355\u20131357 (2014).","journal-title":"Leukemia"},{"key":"1460_CR25","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1158\/0008-5472.CAN-14-2930","volume":"75","author":"Q Zhou","year":"2015","unstructured":"Zhou, Q. et al. A chemical genetics approach for the functional assessment of novel cancer genes. Cancer Res. 75, 1949\u20131958 (2015).","journal-title":"Cancer Res."},{"key":"1460_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","volume":"30","author":"EA Obeng","year":"2016","unstructured":"Obeng, E. A. et al. Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell 30, 404\u2013417 (2016).","journal-title":"Cancer Cell"},{"key":"1460_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4493","volume":"24","author":"M Seiler","year":"2018","unstructured":"Seiler, M. et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat. Med. 24, 497\u2013504 (2018).","journal-title":"Nat. Med."},{"key":"1460_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.35.15_suppl.tps7075","author":"DP Steensma","year":"2018","unstructured":"Steensma, D. P. et al. H3B-8800-G0001-101: a first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies. J. Clin. Oncol., https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.tps7075 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1460_CR29","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","volume":"35","author":"DP Steensma","year":"2021","unstructured":"Steensma, D. P. et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia 35, 3542\u20133550 (2021).","journal-title":"Leukemia"},{"key":"1460_CR30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-019-1646-9","volume":"574","author":"D Inoue","year":"2019","unstructured":"Inoue, D. et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature 574, 432\u2013436 (2019).","journal-title":"Nature"},{"key":"1460_CR31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/2159-8290.CD-19-1330","volume":"10","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization. Cancer Discov. 10, 806\u2013821 (2020).","journal-title":"Cancer Discov."},{"key":"1460_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138315","author":"B Liu","year":"2020","unstructured":"Liu, B. et al. Mutant SF3B1 promotes AKT and NF-kB driven mammary tumorigenesis. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI138315 (2020).","journal-title":"J. Clin. Invest."},{"key":"1460_CR33","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1172\/JCI125022","volume":"129","author":"WB Dalton","year":"2019","unstructured":"Dalton, W. B. et al. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. J. Clin. Invest. 129, 4708\u20134723 (2019).","journal-title":"J. Clin. Invest."},{"key":"1460_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2159-8290.CD-17-0603","volume":"8","author":"I Bajrami","year":"2018","unstructured":"Bajrami, I. et al. E-Cadherin\/ROS1 inhibitor synthetic lethality in breast cancer. Cancer Discov. 8, 498\u2013515 (2018).","journal-title":"Cancer Discov."},{"key":"1460_CR35","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588\u20135599 (2012).","journal-title":"Cancer Res."},{"key":"1460_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03917-2","volume":"9","author":"SJ Pettitt","year":"2018","unstructured":"Pettitt, S. J. et al. Genome-wide and high-density CRISPR\u2013Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat. Commun. 9, 1849 (2018).","journal-title":"Nat. Commun."},{"key":"1460_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.gde.2019.03.001","volume":"54","author":"SJ Pettitt","year":"2019","unstructured":"Pettitt, S. J. & Lord, C. J. Dissecting PARP inhibitor resistance with functional genomics. Curr. Opin. Genet. Dev. 54, 55\u201363 (2019).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"1460_CR38","doi-asserted-by":"publisher","first-page":"19304","DOI":"10.1073\/pnas.0909345106","volume":"106","author":"CA Lovejoy","year":"2009","unstructured":"Lovejoy, C. A. et al. Functional genomic screens identify CINP as a genome maintenance protein. Proc. Natl Acad. Sci. USA 106, 19304\u201319309 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1460_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjh.14793","volume":"182","author":"G Pratt","year":"2018","unstructured":"Pratt, G. et al. A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br. J. Haematol. 182, 429\u2013433 (2018).","journal-title":"Br. J. Haematol."},{"key":"1460_CR40","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich, K. A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9, 616\u2013627 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1460_CR41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard, H., Garcia-Muse, T. & Aguilera, A. Replication stress and cancer. Nat. Rev. Cancer 15, 276\u2013289 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1460_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza, A. et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature 559, 279\u2013284 (2018).","journal-title":"Nature"},{"key":"1460_CR43","doi-asserted-by":"publisher","first-page":"20752","DOI":"10.1073\/pnas.0806917106","volume":"105","author":"D Wilsker","year":"2008","unstructured":"Wilsker, D., Petermann, E., Helleday, T. & Bunz, F. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc. Natl Acad. Sci. USA 105, 20752\u201320757 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1460_CR44","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.molcel.2016.10.037","volume":"64","author":"R Bhowmick","year":"2016","unstructured":"Bhowmick, R., Minocherhomji, S. & Hickson, I. D. RAD52 facilitates mitotic DNA synthesis following replication stress. Mol. Cell 64, 1117\u20131126 (2016).","journal-title":"Mol. Cell"},{"key":"1460_CR45","doi-asserted-by":"publisher","first-page":"25172","DOI":"10.1074\/jbc.M302882200","volume":"278","author":"A Ciccia","year":"2003","unstructured":"Ciccia, A., Constantinou, A. & West, S. C. Identification and characterization of the human mus81-eme1 endonuclease. J. Biol. Chem. 278, 25172\u201325178 (2003).","journal-title":"J. Biol. Chem."},{"key":"1460_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01180-5","volume":"8","author":"D Lemacon","year":"2017","unstructured":"Lemacon, D. et al. MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells. Nat. Commun. 8, 860 (2017).","journal-title":"Nat. Commun."},{"key":"1460_CR47","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.molcel.2017.12.029","volume":"69","author":"L Chen","year":"2018","unstructured":"Chen, L. et al. The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations. Mol. Cell 69, 412\u2013425 (2018).","journal-title":"Mol. Cell"},{"key":"1460_CR48","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-17-3970","volume":"78","author":"HD Nguyen","year":"2018","unstructured":"Nguyen, H. D. et al. Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndromes. Cancer Res. 78, 5363\u20135374 (2018).","journal-title":"Cancer Res."},{"key":"1460_CR49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9, 400\u2013414 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"1460_CR50","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1101\/gad.348479.121","volume":"35","author":"A Simoneau","year":"2021","unstructured":"Simoneau, A., Xiong, R. & Zou, L. The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1\/2-deficient cells. Genes Dev. 35, 1271\u20131289 (2021).","journal-title":"Genes Dev"},{"key":"1460_CR51","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","volume":"14","author":"AC Mita","year":"2008","unstructured":"Mita, A. C., Mita, M. M., Nawrocki, S. T. & Giles, F. J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 14, 5000\u20135005 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1460_CR52","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1158\/0008-5472.CAN-07-0494","volume":"67","author":"RH Stauber","year":"2007","unstructured":"Stauber, R. H., Mann, W. & Knauer, S. K. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 67, 5999\u20136002 (2007).","journal-title":"Cancer Res."},{"key":"1460_CR53","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1111\/j.1755-3768.2009.01769.x","volume":"89","author":"M Angi","year":"2011","unstructured":"Angi, M. et al. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol. 89, e155\u2013e160 (2011).","journal-title":"Acta Ophthalmol."},{"key":"1460_CR54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ceb.2009.01.018","volume":"21","author":"HC Reinhardt","year":"2009","unstructured":"Reinhardt, H. C. & Yaffe, M. B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. Cell Biol. 21, 245\u2013255 (2009).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1460_CR55","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1158\/1535-7163.MCT-17-0098","volume":"16","author":"A Drean","year":"2017","unstructured":"Drean, A. et al. Modeling therapy resistance in BRCA1\/2-mutant cancers. Mol. Cancer Ther. 16, 2022\u20132034 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"1460_CR56","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.15252\/embj.201696082","volume":"36","author":"H Jaiswal","year":"2017","unstructured":"Jaiswal, H. et al. ATM\/Wip1 activities at chromatin control Plk1 re-activation to determine G2 checkpoint duration. EMBO J. 36, 2161\u20132176 (2017).","journal-title":"EMBO J."},{"key":"1460_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10460-1","volume":"10","author":"H Fleury","year":"2019","unstructured":"Fleury, H. et al. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat. Commun. 10, 2556 (2019).","journal-title":"Nat. Commun."},{"key":"1460_CR58","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.molonc.2014.06.004","volume":"8","author":"N Amirouchene-Angelozzi","year":"2014","unstructured":"Amirouchene-Angelozzi, N. et al. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. Mol. Oncol. 8, 1508\u20131520 (2014).","journal-title":"Mol. Oncol."},{"key":"1460_CR59","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0555","author":"J Bigot","year":"2021","unstructured":"Bigot, J. et al. Splicing patterns in SF3B1 mutated uveal melanoma generate shared immunogenic tumor-specific neo-epitopes. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0555 (2021).","journal-title":"Cancer Discov."},{"key":"1460_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29043-z","volume":"8","author":"H Holme","year":"2018","unstructured":"Holme, H. et al. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Sci. Rep. 8, 10614 (2018).","journal-title":"Sci. Rep."},{"key":"1460_CR61","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.molcel.2015.09.012","volume":"60","author":"RA Schwab","year":"2015","unstructured":"Schwab, R. A. et al. The Fanconi anemia pathway maintains genome stability by coordinating replication and transcription. Mol. Cell 60, 351\u2013361 (2015).","journal-title":"Mol. Cell"},{"key":"1460_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1460_CR63","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"1460_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","journal-title":"Genome Biol."},{"key":"1460_CR65","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"1460_CR66","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/bioinformatics\/btw076","volume":"32","author":"A Kahles","year":"2016","unstructured":"Kahles, A., Ong, C. S., Zhong, Y. & Ratsch, G. SplAdder: identification, quantification and testing of alternative splicing events from RNA-seq data. Bioinformatics 32, 1840\u20131847 (2016).","journal-title":"Bioinformatics"},{"key":"1460_CR67","doi-asserted-by":"publisher","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","volume":"111","author":"S Shen","year":"2014","unstructured":"Shen, S. et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-seq data. Proc. Natl Acad. Sci. USA 111, E5593\u2013E5601 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1460_CR68","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1460_CR69","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1093\/bioinformatics\/btx469","volume":"33","author":"O Wagih","year":"2017","unstructured":"Wagih, O. ggseqlogo: a versatile R package for drawing sequence logos. Bioinformatics 33, 3645\u20133647 (2017).","journal-title":"Bioinformatics"},{"key":"1460_CR70","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1093\/bioinformatics\/btp340","volume":"25","author":"C Zang","year":"2009","unstructured":"Zang, C. et al. A clustering approach for identification of enriched domains from histone modification ChIP\u2013seq data. Bioinformatics 25, 1952\u20131958 (2009).","journal-title":"Bioinformatics"},{"key":"1460_CR71","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"ENCODE Project Consortium","year":"2012","unstructured":"ENCODE Project Consortium An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57\u201374 (2012).","journal-title":"Nature"},{"key":"1460_CR72","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-023-01460-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-023-01460-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-023-01460-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T13:11:56Z","timestamp":1691586716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-023-01460-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1038\/s41588-023-01460-5","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.N. is a named inventor on a patent describing the use of EXD2 inhibitors and stands to gain from their development as part of the ICR \u2018Rewards to Inventors\u2019 scheme, and was a consultant for MNM Bioscience. C.J.L. makes the following disclosures: receives and\/or has received research funding from AstraZeneca, Merck KGaA, and Artios; received consultancy from SAB membership or honoraria payments from Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate and Dark Blue Therapeutics; has stock in Tango, Ovibio, Enedra Tx., Hysplex and Tesselate. C.J.L. is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR \u2018Rewards to Inventors\u2019 scheme and also reports benefits from this scheme associated with patents for PARPi paid into CJL\u2019s personal account and research accounts at the Institute of Cancer Research. R.N. receives and\/or has received academic research funding from Pfizer in the form of the Breast Cancer Now Catalyst academic grant scheme. AstraZeneca partially supported the PiCCLe clinical trial (supplied by Olaparib; this study is published). The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}